Evidence map›Paper›PMID 32840737›Full record

ArticleMolecular and cellular biochemistry2020

Farrerol maintains the contractile phenotype of VSMCs via inactivating the extracellular signal-regulated protein kinase 1/2 and p38 mitogen-activated protein kinase signaling.

Enli Liu, Shasha Shi, Jie Li, Rui Ge, Taigang Liang, Qingshan Li

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular and cellular biochemistry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Enli LiuSchool of Pharmaceutical Science, Shanxi Medical University, 56 Xinjian South Road, Tai Yuan, 030001, Shan xi, China.ORCID http://orcid.org/0000-0002-4279-0165
Shasha ShiSchool of Pharmaceutical Science, Shanxi Medical University, 56 Xinjian South Road, Tai Yuan, 030001, Shan xi, China.
Jie LiSchool of Pharmaceutical Science, Shanxi Medical University, 56 Xinjian South Road, Tai Yuan, 030001, Shan xi, China.
Rui GeSchool of Pharmaceutical Science, Shanxi Medical University, 56 Xinjian South Road, Tai Yuan, 030001, Shan xi, China.
Taigang LiangSchool of Pharmaceutical Science, Shanxi Medical University, 56 Xinjian South Road, Tai Yuan, 030001, Shan xi, China.
Qingshan LiSchool of Pharmaceutical Science, Shanxi Medical University, 56 Xinjian South Road, Tai Yuan, 030001, Shan xi, China. sxyxlqs@163.com.ORCID http://orcid.org/0000-0003-3665-5175

Funding

the National Natural Science Foundation of China no. 81172938The Natural Science Foundation for Young Scientists of Shanxi Province 201601D021158the Shanxi Key Laboratory of Innovative Drug for the Treatment of Serious Diseases Basing on the Chronic Inflammation (Shanxi University of Chinese Medicine) SXIDL-2018-03
6 · The paper itself

Abstract

Farrerol, a dihydroflavone isolated from Rhododendron dauricum L., can inhibit vascular smooth muscle cell (VSMC) proliferation and exert a protective effect on H

Indexed as

AnimalsAortaCells, CulturedChromonesDisease Models, AnimalMaleMitogen-Activated Protein Kinase 1Mitogen-Activated Protein Kinase 3Muscle ContractionMuscle, Smooth, VascularNeointimap38 Mitogen-Activated Protein KinasesPhosphorylationPhytochemicalsRatsRats, Sprague-DawleyChromonesfarrerolMapk1 protein, ratMitogen-Activated Protein Kinase 1Mitogen-Activated Protein Kinase 3p38 Mitogen-Activated Protein KinasesPhytochemicalsERK1/2FarrerolIntimal hyperplasiap38 MAPKPhenotypic transitionVascular smooth muscle cells

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.